Cipla in talks to repurpose drugs for Monkeypox, Q1 profit falls 4% to ₹686 cr

Cipla reported net profit of ₹686 crore during for the quarter ended June, down 4% from ₹715 crore for the first quarter of FY22, mainly due to sharp normalisation in Covid portfolio contribution. Its first quarter revenue dropped 2% year on year to ₹5,375 crore from ₹5,504 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6kfTGX8
via IFTTT